Returns Breakdown
3.97
Return on Assets
12.04
Return on Investment
| Return on Investment | 12.04 | |
| Return on Assets | 3.97 | |
| Return on Equity | 19.77 | |
| Return Capital | 0.16 | |
| Return on Sales | 0.12 |
Estimating Mednax (USA Stocks:MD) price for March 2023.
 | By Gabriel Shpitalnik | Macroaxis Story |
Mednax Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 2.99 Billion. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 307 M, whereas Earnings before Tax are forecasted to decline to about 127.2 M. Today's short post will digest Mednax as your potential position. We will discuss the question of why shareholders should continue to be confident in Mednax outlook.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Mednax Inc has a beta of 1.0866. Let's try to break down what Mednax's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mednax will likely underperform. The beta indicator helps investors understand whether Mednax moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Mednax deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Mednax. Your research has to be compared to or analyzed against Mednax's peers to derive any actionable benefits. When done correctly, Mednax's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Mednax Inc.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Mednax Inc. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Mednax
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mednax's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Mednax's Liquidity
Mednax financial leverage refers to using borrowed capital as a funding source to finance Mednax Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mednax financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Mednax's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Mednax's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Mednax's total debt and its cash.
Mednax Gross Profit
Mednax Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Mednax previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Mednax Gross Profit growth over the last 10 years. Please check Mednax's gross profit and other fundamental indicators for more details.
Is Mednax valued correctly by the market?
Mednax Inc exhibits very low volatility with skewness of -0.21 and kurtosis of -0.69. However, we advise investors to further study Mednax Inc technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mednax's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mednax's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Mednax Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.